The evaluation will be conducted at Quanterix and will focus on an undisclosed neuron-specific protein target.
Quanterix CEO David Okrongly said they are excited to initiate this technology evaluation with Novartis, one of the world’s leading healthcare companies.
"This partnership is an important milestone for Quanterix, and another step toward our goal to be the recognized global leader in sensitive and precise detection technology," Okrongly said.
"Through this collaborative project, we hope to leverage the 1000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes."
